Concord Biotech Faces Evaluation Shift Amid Declining Sales and Profit Metrics
Concord Biotech has experienced a recent evaluation adjustment, reflecting changes in its technical indicators. The company has faced challenges in its quarterly results, with declines in profit and net sales. Institutional investor participation has also decreased slightly, indicating shifting market sentiments regarding its growth prospects.
Concord Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting changes in its technical indicators. The stock's technical trend has shifted from bearish to mildly bearish, indicating a nuanced perspective on its market position.In terms of performance metrics, Concord Biotech has faced challenges, particularly in its recent quarterly results. The company reported a significant decline in profit before tax and net sales, with figures falling sharply compared to previous quarters. Despite a return on equity of 18.1, which suggests a level of management efficiency, the stock's valuation appears elevated when compared to its peers, with a price-to-book ratio of 9.2.
Institutional investor participation has also seen a slight decrease, with a 0.54% reduction in stake over the last quarter, bringing their collective ownership to 17.97%. This trend may reflect broader market sentiments regarding the company's long-term growth prospects.
Overall, while Concord Biotech maintains a high level of management efficiency, the recent evaluation adjustment highlights the complexities of its current market standing and financial performance.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
